Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$6.37 - $15.23 $12,396 - $29,637
1,946 Added 10.2%
21,023 $318,000
Q2 2022

Aug 15, 2022

SELL
$4.95 - $9.16 $1,326 - $2,454
-268 Reduced 1.39%
19,077 $143,000
Q1 2022

May 16, 2022

SELL
$5.64 - $9.8 $411 - $715
-73 Reduced 0.38%
19,345 $176,000
Q4 2021

Feb 14, 2022

SELL
$7.02 - $13.33 $11,505 - $21,847
-1,639 Reduced 7.78%
19,418 $137,000
Q3 2021

Nov 15, 2021

BUY
$11.32 - $16.63 $36,857 - $54,147
3,256 Added 18.29%
21,057 $240,000
Q2 2021

Aug 17, 2021

BUY
$15.16 - $18.97 $269,863 - $337,684
17,801 New
17,801 $285,000
Q1 2021

May 17, 2021

SELL
$13.12 - $20.9 $225,624 - $359,417
-17,197 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$9.12 - $14.49 $48,454 - $76,985
5,313 Added 44.71%
17,197 $233,000
Q3 2020

Nov 16, 2020

SELL
$10.46 - $14.46 $2,374 - $3,282
-227 Reduced 1.87%
11,884 $140,000
Q2 2020

Aug 14, 2020

SELL
$12.0 - $16.13 $13,116 - $17,630
-1,093 Reduced 8.28%
12,111 $179,000
Q1 2020

May 15, 2020

SELL
$11.84 - $25.52 $9.8 Million - $21.1 Million
-827,332 Reduced 98.43%
13,204 $179,000
Q4 2019

Feb 14, 2020

SELL
$17.72 - $25.1 $762,137 - $1.08 Million
-43,010 Reduced 4.87%
840,536 $20.3 Million
Q3 2019

Nov 14, 2019

SELL
$18.41 - $28.0 $508,870 - $773,948
-27,641 Reduced 3.03%
883,546 $17 Million
Q2 2019

Aug 14, 2019

SELL
$28.97 - $48.21 $15.6 Million - $26 Million
-539,758 Reduced 37.2%
911,187 $26.9 Million
Q1 2019

May 15, 2019

BUY
$36.32 - $49.25 $12.8 Million - $17.4 Million
352,638 Added 32.11%
1,450,945 $68.9 Million
Q4 2018

Feb 14, 2019

BUY
$33.0 - $60.04 $36.2 Million - $65.9 Million
1,098,307 New
1,098,307 $39.6 Million

Others Institutions Holding AERI

About AERIE PHARMACEUTICALS INC


  • Ticker AERI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 49,390,500
  • Description
  • Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...
More about AERI
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.